What if you could identify top clones, in just days?

The Opto™ CLD 2.0 workflow helps you avoid traditional laborious, inefficient well plate workflows. You can now select top clones with >99% monoclonality assurance in just days – even for non-traditional antibodies.

Get a quick breakdown of this workflow from expert, Anupam Singhal, PhD in his video tour.

Take the Tour

high-performance clones, with >99% monoclonality assurance

Confident clonality assurance for a successful IND

The Beacon system’s optofluidic chip technology and integrated imaging provide direct evidence of FDA-accepted >99% monoclonality, without the manual effort and uncertainty of traditional methods. Learn how the Opto CLD workflow provides superior cloning technology and in-process quality controls for definitive evidence of monoclonality to support regulatory approvals.

Read the Application Note

 

Optimizing therapeutic production when every day matters

What’s the future of vaccine and therapeutic development? The race to provide COVID-19 treatments will change the way we approach future therapy development. Watch our on-demand fireside chat, for an in-depth discussion on fast-tracking the development of therapeutic antibodies and vaccines for SARS-Cov-2. Distinguished guests include Dr. Jennitte Stevens from Amgen, Dr. Gregory Bleck from Catalent Biologics, and Dr. Trent Munro from the University of Queensland.

Watch the Fireside Chat

Find out more about how the Opto CLD workflow addresses your pain points. Just fill out the short form below and a specialist will reach out within 24 hours.